Adage Capital Partners’s Mirum Pharmaceuticals MIRM Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$14.9M Sell
174,762
-175,238
-50% -$18.3M 0.02% 621
2026
Q2
$41M Sell
350,000
-25,000
-7% -$2.51M 0.06% 330
2026
Q1
$34.6M Sell
375,000
-92,468
-20% -$8.7M 0.05% 332
2025
Q4
$36.9M Sell
467,468
-30,000
-6% -$2.15M 0.06% 321
2025
Q3
$36.5M Buy
497,468
+254,468
+105% +$16.2M 0.06% 308
2025
Q2
$12.4M Sell
243,000
-102,000
-30% -$4.54M 0.02% 568
2025
Q1
$15.5M Buy
345,000
+195,000
+130% +$9.19M 0.03% 476
2024
Q4
$6.2M Buy
150,000
+70,000
+88% +$2.92M 0.01% 692
2024
Q3
$3.12M Sell
80,000
-80,000
-50% -$3.19M 0.01% 752
2024
Q2
$5.47M Hold
160,000
– – 0.01% 703
2024
Q1
$4.02M Sell
160,000
-415,000
-72% -$11.4M 0.01% 720
2023
Q4
$17M Sell
575,000
-90,000
-14% -$2.72M 0.04% 468
2023
Q3
$21M Buy
+665,000
New +$18.2M 0.05% 381

Other funds holding MIRM

Adage Capital Partners's MIRM Position: Q3 2026 in Review

Adage Capital Partners reduced its Mirum Pharmaceuticals (MIRM) stake by 50% in Q3 2026, selling an estimated $18.3M and leaving 174,762 shares worth $14.9M. The position accounts for 0.02% of the portfolio, ranked #621.

Adage Capital Partners first reported a position in MIRM in Q3 2023 and has held it in 13 quarters since. The position peaked at $41M in Q2 2026. 317 funds tracked by Wall St. Rank hold MIRM as of Q3 2026.

  • Adage Capital Partners held 174,762 shares of Mirum Pharmaceuticals worth $14.9M as of Q3 2026.
  • Adage Capital Partners sold 175,238 Mirum Pharmaceuticals shares in Q3 2026, an estimated $18.3M.
  • Mirum Pharmaceuticals made up 0.02% of Adage Capital Partners's portfolio in Q3 2026, its #621 holding.
  • Adage Capital Partners first reported a position in Mirum Pharmaceuticals in Q3 2023 and has held it in 13 quarters since.
  • Adage Capital Partners's Mirum Pharmaceuticals position peaked at $41M in Q2 2026.
  • 317 funds tracked by Wall St. Rank held Mirum Pharmaceuticals as of Q3 2026.

Based on Adage Capital Partners's 13F filing for Q3 2026, filed 16 Nov 2026.